FDA Investigator Jonee J Mearns

Jonee J Mearns has conducted inspections on 80 sites in 7 countries as of 08 May 2015. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
80
Last Inspection Date:
08 May 2015
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, France, El Salvador, Germany, Romania, Belgium, Hungary
FDA Investigators that have inspected at least one site in common with Jonee J Mearns:
Addam S Reynolds, Adetutu M Gidado, Alberto A Viciedo, Alexandra B Pitkin, Allen Lou, Amatul H Marium, Amy Kim, Amy L Singer, Amy M Cramer, Amy Wyan Mai, Ana S Cabrera, Anastasia I Offordile, Andria L Kuhlman, Ann Marie Montemurro, Ann Marie Schofield, Annet R Rajan, Anthony J Donato, Anthony N Onianwa, Arindam Dasgupta, PhD, Azza Talaat, Barbara J Maulfair, Bei Yu, Betsy C Galliher, Bill Tacket, Jr, Byungja E Marciante, Christina N Maurino, Christina P Burkhart, Connie R Kiessling, Craig A Garmendia, Cynthia F Kleppinger, MD, Daniel J Grabicki, Darin S Wiegers, David H Smith, Dawn L Wydner, Deborah B Nixon, Denise M Visco, Investigator, Diane B Radice, Doreen P Canetti, Doreen P Gubbay, Dorothy J Denes, Douglas C Kovacs, Dr. Abhijit Raha, PhD, Dr. Sriram Subramaniam, PhD, Edward O'shaughnessy, Edwin Melendez, Emest F Bizjak, Emily A Walters, Emmanuel Jramos Maldonado, Erica L Nicoll, Erin D Mccaffery, Esteban Beltran, Frank J Marciniak, Frederick F Razzaghi, Gajendiran Mahadevan, PhD, Guerlain Ulysse, Helen B Ricalde, Hyojong Kwon, PhD, Jacqueline A O'shaughnessy, PhD, James M Kewley, James P Mcevoy, James R Birkenstamm, Janete F Guardia, Jean M Kelahan, Jean M Mulinde, MD, Jennifer A Bazergui, Jennifer L Custodio, Jennifer Macmillan, Jessica M Monteiro, Jocelyn E Massey, Jose Acruz Gonzalez, Joseph F Mcginnis, RPh, Joseph L Despins, PhD, Joy Rkozlowski Klena, Justine Tomasso, Kara A Scheibner, PhD, Karen E D'orazio, Keith M Reilly, Kelli F Dobilas, Kelly I Anderson, Kinh Q Mac, Kip J Hanks, Kristen E Rescigno, Kristy A Zielny, Krystal O Ogunremi, Lata C Mathew, PhD, Lauren L Vajo, Lawrence R Johnson, Li Li, Liatte Kreuger, PharmD, Libia M Lugo, Linda R Kuchenthal, Lisa Harlan, Lisa Hayka, Lisa Mathew, Loretta Nemchik, Marcelo O Mangalindan, Jr, Marea K Harmon, Margaret M Sands, Margarita Santiago, Maria Estrella, Martin K Yau, PhD, Matthew B Casale, Melba Trivera Clavell, Melissa B Libby, Michael F Skelly, PhD, Michael R Klapal, Michael Serrano, Michelle M Noe Varga, Miguel A Martinez Perez, Mohsen Rajabi Abhari, FDA, Monica L Gutierrez, Nadeem I Chaudhry, Namita Kothary, Nancy F Scheraga, Nancy L Rolli, Nerizza B Dalena, Nerizza B Guerin, Nicholas A Violand, Niketa Patel, Nilufer M Tampal, PhD, Nina Yang, Norman Wong, Patricia A Mcilroy, Paul L Bellamy, Paul L Figarole, Jr, Peter R Lenahan, Rafael E Arroyo, Raymond L Cheung, Regina T Brown, Richard A Abate, Richard W Berning, Robert G Ruff, Robert Jennings, Roger J Adams, Sam Chan, Sarah Forney, Schultz, Sharon L Matson, Shirley S Wen, Sinai I Davis, Spiridoula Dimopoulos, Stephanie T Durso, Stephen J Mottola, Steven A Gonzales, Tara G Bizjak, Tara R Gooen, Tyanna N Hadley, Valerie C Reed, Valerie Reed, Victoria Spivak, William J Muszynski, Xiaohan Cai, PhD, Xiaokuang Lai, PhD, Yangmin Ning, Yuanyuan Li, Zachary L Miller

Jonee J Mearns's Documents

Publish Date Document Type Title
May, 2014 EIR Bausch Health Companies, Inc. - EIR, 2014-05-19
February, 2015 FDA 483 Merck Sharp & Dohme LLC - Form 483, 2015-02-23
April, 2012 FDA 483 Bristol Myers Squibb - Form 483, 2012-04-05
August, 2011 FDA 483 Access Bio, Inc. - Form 483, 2011-09-12
January, 2009 FDA 483 Bristol Myers Squibb - Form 483, 2009-01-30
January, 2012 FDA 483 Capital Health - Form 483, 2012-01-27
September, 2014 FDA 483 Response Daiichi Sankyo, Inc. - Form 483R, 2014-09-30
March, 2009 EIR Johnson & Johnson Pharmaceutical Research & Development, LLC - EIR, 2009-03-24
April, 2015 FDA 483 Response Gregory J. Tracey, M.D. - Form 483R, 2015-04-29
September, 2012 FDA 483 Celgene Corporation - Form 483, 2012-09-12
March, 2012 FDA 483 BRACCO DIAGNOSTICS INC - Form 483, 2012-03-08
March, 2012 EIR BRACCO DIAGNOSTICS INC - EIR, 2012-03-08
April, 2015 EIR Gregory J. Tracey, M.D. - EIR, 2015-04-15
April, 2012 EIR Bristol Myers Squibb - EIR, 2012-04-05
May, 2014 FDA 483 Response Bausch Health Companies, Inc. - Form 483R, 2014-06-05
August, 2011 EIR PAREXEL International GmbH - EIR, 2011-08-05
August, 2010 FDA 483 Radpharm, Inc. - Form 483, 2010-09-02
March, 2009 FDA 483 Johnson & Johnson Pharmaceutical Research & Development, LLC - Form 483, 2009-03-27
May, 2012 EIR Sanofi US - EIR, 2012-05-17
September, 2014 FDA 483 Daiichi Sankyo, Inc. - Form 483, 2014-09-09
January, 2012 EIR Capital Health - EIR, 2012-01-27
April, 2013 FDA 483 Shua-Haim, Joshua R. MD - Form 483, 2013-04-02
April, 2014 FDA 483 Pure Edge Nutrition LLC. - Form 483, 2014-04-22
November, 2014 FDA 483 Christelle Fouchardiere - Form 483, 2014-11-21
September, 2012 EIR Celgene Corporation - EIR, 2012-09-12
July, 2014 FDA 483 Rajesh Sachdeo - Form 483, 2014-07-29
March, 2009 EIR Johnson & Johnson Pharmaceutical Research & Development, LLC - EIR, 2009-03-27
May, 2014 FDA 483 Bausch Health Companies, Inc. - Form 483, 2014-05-19
April, 2015 FDA 483 Gregory J. Tracey, M.D. - Form 483, 2015-04-15

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more